drugset / Trial / NCT05975645
A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
NaSingle-groupOpen-labelTreatment
Summary
This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQB2618 injection combined with penpulimab injection and Anlotinib Hydrochloride Capsules in patients with advanced HCC.
Timeline
- Start
- 2023-08-15
- Primary completion
- 2025-06-04
- Completion
- 2025-06-04
Outcome
Outcome not reported
Stopped (Business): “This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | TQB2618 | Monoclonal antibody | 1200 mg | Intravenous |